2017 BioProcess International Industry Yearbook
The biopharmaceutical industry must find a way to reduce overall development costs and time to market. Technology is the key and industry suppliers are the main source of technology — they are critical partners and the key to your success. For this reason, BioProcess International dedicates one issue each year, the Industry Yearbook, to showcase the technologies, products, and equipment that can help you improve your processes and ultimately, reduce your cost and time to market.
FEATURED REPORT: The BPI Theater @ BIO 2017
The 2017 BPI Theater @ BIO took place June 20-22 in San Diego CA and focused on two main themes: emerging therapies and emerging technologies. The BPI Theater provides convention attendees working and interested in biopharmaceutical research, development and manufacturing with a dedicated destination to meet, network, and experience the latest science and technology trends impacting bioprocessing. Summaries of the presentations were included in the July-August Featured Report, and full video presentations are available for on-demand viewing.
A biosimilar biotherapeutic product is similar (but not identical) in terms of quality, safety, and efficacy to an already licensed reference product. Unlike generic small molecules, it is difficult to standardize such inherently complex products based on complicated manufacturing processes. Table 1 describes the main differences between biosimilar and generic drug molecules. The global biosimilar market is growing rapidly as patents on blockbuster biologic drugs expire (Table 2) and other healthcare sectors focus on reduction of costs. Biologics are among…